Greatest International Antiinfective Trial With Avelox

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-02-29

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchitis, Chronic Bronchial Diseases

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Non-Interventional Observational NIS Moxifloxacin MXF Avelox AECB

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Moxifloxacin (Avelox, BAY12-8039)

Intervention Type DRUG

AECB patients under daily life treatment receiving moxifloxacin according to the local product information.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Moxifloxacin (Avelox, BAY12-8039)

AECB patients under daily life treatment receiving moxifloxacin according to the local product information.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatients with diagnosis of AECB and decision taken by the investigator to prescribe moxifloxacin

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Medical Affairs Therapeutic Area Head

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Many Locations, , Austria

Site Status

Many Locations, , Brazil

Site Status

Many Locations, , China

Site Status

Many Locations, , Colombia

Site Status

Many Locations, , Croatia

Site Status

Many Locations, , Egypt

Site Status

Many Locations, , El Salvador

Site Status

Many Locations, , Germany

Site Status

Many Locations, , Hong Kong

Site Status

Many Locations, , Hungary

Site Status

Many Locations, , Indonesia

Site Status

Many Locations, , Malaysia

Site Status

Many Locations, , Mexico

Site Status

Many Locations, , Morocco

Site Status

Many Locations, , Netherlands

Site Status

Many Locations, , Pakistan

Site Status

Many Locations, , Philippines

Site Status

Many Locations, , Poland

Site Status

Many Locations, , Singapore

Site Status

Many Locations, , Slovenia

Site Status

Many Locations, , South Korea

Site Status

Many Locations, , Switzerland

Site Status

Many Locations, , Taiwan

Site Status

Many Locations, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Brazil China Colombia Croatia Egypt El Salvador Germany Hong Kong Hungary Indonesia Malaysia Mexico Morocco Netherlands Pakistan Philippines Poland Singapore Slovenia South Korea Switzerland Taiwan Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Anzueto A, Miravitlles M, Ewig S, Legnani D, Heldner S, Stauch K. Identifying patients at risk of late recovery (>/= 8 days) from acute exacerbation of chronic bronchitis and COPD. Respir Med. 2012 Sep;106(9):1258-67. doi: 10.1016/j.rmed.2012.06.002. Epub 2012 Jun 30.

Reference Type RESULT

PMID: 22749710 (View on PubMed)